Nordea Investment Management AB Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)

Nordea Investment Management AB increased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 4.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 125,400 shares of the company’s stock after buying an additional 5,300 shares during the quarter. Nordea Investment Management AB owned about 0.15% of CRISPR Therapeutics worth $4,913,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in CRSP. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics in the second quarter valued at about $35,000. National Bank of Canada FI lifted its position in CRISPR Therapeutics by 35.0% in the second quarter. National Bank of Canada FI now owns 848 shares of the company’s stock valued at $46,000 after purchasing an additional 220 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in CRISPR Therapeutics in the third quarter valued at about $40,000. Darwin Wealth Management LLC acquired a new stake in CRISPR Therapeutics in the third quarter valued at about $43,000. Finally, Elkhorn Partners Limited Partnership acquired a new stake in CRISPR Therapeutics in the second quarter valued at about $54,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insiders Place Their Bets

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Samarth Kulkarni sold 15,000 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now directly owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 50,382 shares of company stock valued at $2,744,179. Company insiders own 4.10% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on CRSP shares. Barclays reduced their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. JMP Securities restated a “market outperform” rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Chardan Capital reiterated a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $78.38.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock opened at $39.69 on Friday. CRISPR Therapeutics AG has a 1 year low of $38.20 and a 1 year high of $91.10. The company has a market capitalization of $3.39 billion, a P/E ratio of -14.02 and a beta of 1.68. The business has a 50 day moving average price of $46.39 and a 200 day moving average price of $48.83.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million during the quarter, compared to the consensus estimate of $6.65 million. During the same period in the previous year, the firm posted ($1.41) EPS. As a group, research analysts expect that CRISPR Therapeutics AG will post -5.13 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.